Purpose: To determine the long-term efficacy and reliability of intravitreal bevacizumab injection in neovascular glaucoma.

Materials and Methods: Eighteen eyes of twelve patients (8 men, 4 women) with diagnosis of neovascular glaucoma were included in this study group. Twelve eyes had proliferative diabetic retinopathy (66.7%) and 6 eyes (33.3%) had central retinal vein occlusion. Intravitreal bevacizumab (1.25 mg/0.05 ml, Altuzan) was injected in all eyes after the completion of laser therapy. Best-corrected visual acuity (BCVA) and intraocular pressure (IOP) were measured before and at 1^st week, 1^st month, 3^rd month, and 6^th month after the injection; and anterior segment angiography images were obtained before and at the 1^st week, 3^rd month and 6^th month after the injection. Angiographic images were evaluated according to the grading system of iris neovascularization (Stage 0-4).

Results: The decrease of symptoms and regression in grade of neovascularization were determined at the first week in all eyes. The mean IOP values were 26.32±1.37 mmHg, 24.14±2.03 mmHg, 26.78±2.19 mmHg, and 27.72±2.28 mmHg at the 1^st week, 1^st month, 3^rd month, and 6th month after injection, respectively (p<0.05). The mean BCVA was 1.14±0.21 LogMAR (0.7-2.0) at the 6^th month, and there was no significant difference from preinjection values (p>0.05).

Discussion: Intravitreal injection of bevacizumab seems to be effective and safe treatment modality for neovascular glaucoma in long-term period and it can be used as an adjuvant therapy to the panretinal photocoagulation and antiglaucomatous agents.